" class="no-js "lang="en-US"> Eric Le Forestier - Medtech Alert
Thursday, February 06, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
Eric Le Forestier

Eric Le Forestier

About Eric Le Forestier

International experience in Team Development, Quality Assurance, Project Management, Customer Relationship in the Biotech, Pharmaceutical and Vaccine industry.
Curious about the technical, scientific and business aspects of drug manufacturing.
Enjoying diverse cultural, geographical and organizational settings.

Related Story

Clinical Trials

 Naobios Delivers Flugen Inc’s M2SR Influenza Vaccine Candidate for Upcoming Clinical Trials | Pharmtech Focus

Naobios Delivers Flugen Inc’s M2SR Influenza Vaccine Candidate for Upcoming Clinical Trials

June 22 2022

Naobios, a CDMO (Contract Development and Manufacturing Organization) providing bioprocess development and GMP production of […]

Industry News

 Naobios Manufactures FluGen Inc’s M2SR Influenza Vaccine Candidate for Upcoming Clinical Trials | Pharmtech Focus

Naobios Manufactures FluGen Inc’s M2SR Influenza Vaccine Candidate for Upcoming Clinical Trials

September 21 2021

Naobios, a CDMO (Contract Development and Manufacturing Organization) providing bioprocess development and GMP production of […]